Literature DB >> 10744105

Chiral switches.

G T Tucker1.   

Abstract

Developments in synthetic and analytical chemistry have provided the tools to differentiate between two enantiomers (mirror images) of drugs or between the parent compound and metabolite(s) with respect to desired and undesired pharmacological effects. Several drugs are now marketed or being developed as single enantiomers in place of a previous racemic mixture, a process known as "chiral switching". It is easier to understand "pure" as opposed to "mixture" pharmacology but whether the promise of chiral (and metabolite) switches will translate into real clinical advances remains to be seen.

Mesh:

Year:  2000        PMID: 10744105     DOI: 10.1016/S0140-6736(00)02047-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

1.  Chirality and drugs used to treat psychiatric disorders.

Authors:  Glen B Baker; Trevor I Prior; Ronald T Coutts
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

Review 2.  Single-enantiomer drugs: elegant science, disappointing effects.

Authors:  Peter Mansfield; David Henry; Anne Tonkin
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Key factors in the discovery and development of new antiepileptic drugs.

Authors:  Meir Bialer; H Steve White
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

4.  Enantiomeric impurity analysis using circular dichroism spectroscopy with United States Pharmacopeia liquid chromatographic methods.

Authors:  Douglas Kirkpatrick; Margaret Fain; Jingyue Yang; Michael Trehy
Journal:  J Pharm Biomed Anal       Date:  2018-04-24       Impact factor: 3.935

5.  Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.

Authors:  Aneta Doricakova; Dirk Theile; Johanna Weiss; Radim Vrzal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-27       Impact factor: 3.000

6.  Stereoisomers in Psychiatry: The Case of Escitalopram.

Authors:  William J. Burke; Christopher J. Kratochvil
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-02

Review 7.  New formulations of existing antidepressants: advantages in the management of depression.

Authors:  Trevor R Norman; James S Olver
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  Escitalopram versus citalopram: the surprising role of the R-enantiomer.

Authors:  Connie Sánchez; Klaus P Bøgesø; Bjarke Ebert; Elin Heldbo Reines; Claus Braestrup
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

9.  Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review.

Authors:  Aaron S Long; Audrey D Zhang; Caitlin E Meyer; Alexander C Egilman; Joseph S Ross; Joshua D Wallach
Journal:  JAMA Netw Open       Date:  2021-05-03

10.  Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants.

Authors:  Ali A Alkhafaji; Ludovic Trinquart; Gabriel Baron; Moïse Desvarieux; Philippe Ravaud
Journal:  BMC Med       Date:  2012-11-20       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.